Biolayer Interferometry (BLI)

Biolayer Interferometry (BLI) is a label-free, real-time optical biosensing technique that measures molecular interactions by detecting changes in interference patterns of reflected light. The system uses fiber-optic biosensor tips coated with a biocompatible layer (e.g., streptavidin, Ni-NTA, or anti-tag antibodies). When biomolecules bind to the sensor surface, the optical thickness of the layer changes, causing a shift in the interference pattern. This shift is recorded in real time, allowing precise quantification of binding kinetics (association/dissociation rates) and affinity (equilibrium dissociation constant, KD). Unlike traditional methods such as ELISA or SPR, BLI requires no microfluidics, enabling faster setup, lower sample consumption, and greater flexibility in experimental design.

Applications in High-Throughput Screening (HTS)

The initial phase of drug development demands efficient identification of high-affinity hits from extensive compound libraries to facilitate lead optimization. At PharmaAnalytica, we employ Biolayer Interferometry (BLI) technology to enhance the Hit-to-Lead (H2L) screening process through comprehensive analysis of molecular interactions between therapeutic targets (including proteins, antibodies, and membrane receptors) and potential drug candidates (both small molecules and biologics). The real-time detection capability of BLI enables immediate evaluation of binding characteristics, including specificity, stoichiometric relationships, and kinetic parameters, which are critical for selecting compounds with optimal pharmacological profiles. In practical applications, BLI demonstrates exceptional utility in high-throughput antibody screening by rapidly evaluating thousands of clones for antigen-binding capabilities, as well as in fragment-based approaches by detecting low-affinity interactions that can be chemically optimized. Notably, the technology's adaptability extends to complex targets like membrane-associated proteins and multi-protein assemblies, establishing it as an indispensable asset in contemporary drug discovery pipelines.

BLI offers several key advantages for HIT screening. Its label-free nature eliminates interference from fluorescent or radioactive tags, ensuring accurate measurement of intrinsic molecular interactions. The technology's real-time detection provides immediate insights into binding kinetics, distinguishing high-affinity binders from nonspecific interactions. BLI requires minimal sample preparation, as it operates without microfluidics, reducing experimental complexity and turnaround time. The system's low sample consumption (as little as 5–10 µg of protein per assay) is ideal for scarce or expensive biologics. Furthermore, BLI supports high-throughput screening with multi-channel capabilities, enabling parallel analysis of multiple interactions. Its compatibility with diverse sample types (e.g., crude lysates, serum, and cell supernatants) makes it particularly useful for challenging targets. Combined with robust data analysis software, BLI delivers reliable, reproducible results that streamline hit validation and lead optimization.

PharmaAnalytica's Technology Platform

PharmaAnalytica's HIT Screening Services with BLI

PharmaAnalytica stands out by combining cutting-edge BLI platforms with deep expertise in drug discovery.

Cutting-Edge BLI Platforms & Expertise

PharmaAnalytica utilizes state-of-the-art BLI platforms operated by experienced scientists to deliver highly reproducible and reliable data. Our end-to-end solutions cover the entire workflow—from assay development and target immobilization to kinetic profiling and data interpretation.

Scalable Solutions for Diverse Drug Discovery Needs

Whether you're working with small molecules, biologics, or complex targets, PharmaAnalytica's BLI services adapt to your project's scale and complexity. With flexible throughput options and customizable data output formats, we ensure seamless integration with your existing drug discovery pipeline.

Actionable Insights & Rigorous Quality Control

Beyond delivering raw binding data, we provide advanced analytical support, including kinetic modeling, hit prioritization, and structure-activity relationship (SAR) guidance. All experiments undergo strict quality control measures to guarantee high reliability.

Client-Centric Support & Decision-Making Tools

We prioritize clear communication and actionable reporting, delivering: interpretable, publication-ready data summaries, expert consultation to guide hit selection and optimization strategies and tailored project timelines to align with client R&D milestones.

Through the integration of advanced BLI platforms, deep scientific expertise, and tailored client support, we optimize HIT screening into an efficient, data-driven process that accelerates drug discovery timelines.